Cancer Care Ontario | Cancer Care Ontario

The objective of the Medical Physics Residency Program is to train medical physicists to perform duties competently, professionally and safely in a...

Regimen

NIVL+RELA

Cancer Type:

Skin,

Melanoma

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab and Relatlimab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

nivolumab / relatlimab

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Nov 2025

Regimen

MFOLFOX6+ZOLB

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Nov 2025

Guidelines and Advice

Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and the American Society of Clinical Oncology Joint Guideline

Status: Current
ID: GL 1-23-A

Jul 2021

Guidelines and Advice

Management of Ductal Carcinoma in Situ of the Breast

Status: Current
ID: GL1-10
Version: 4

Mar 2024

Metis-Depistage-du-cancer-du-col-luterus-print.pdf

Metis-Depistage-du-cancer-colorectal-print.pdf

Metis-Depistage-cancer-poumon-print.pdf

NIVL+IPIL

NIVL(MNT)

Mouth Care During Cancer Treatment

MATRIX

Medical Physics Residency Program

NIVL+RELA

MFOLFOX6+ZOLB

Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and the American Society of Clinical Oncology Joint Guideline

Management of Ductal Carcinoma in Situ of the Breast

Pages